|
|
|
|
Vol. 55, Issue 6, 1077-1087, June 1999
Institut für Physiologische Chemie I,
Heinrich-Heine-Universität, Düsseldorf, Germany
The transcription factor VDR is the nuclear receptor for
1
,25-dihydroxyvitamin D3 (VD) and the mediator of all
genomic actions of the nuclear hormone and its synthetic analogs. The
sharp biological profile of the model VD analog
1(S),3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene (EB1089) (i.e., its high antiproliferative effect combined with low
calcemic actions) has been correlated with the selectivity of EB1089 to
activate heterodimeric complexes of VDR with its partner retinoid X
receptor (RXR) on VD response elements (VDREs). These VDREs are formed
by an inverted palindromic arrangement of two hexameric core binding
motifs spaced by nine nucleotides (IP9) rather than VDREs that are
formed by direct repeats with three intervening nucleotides (DR3). In
this report, ligand-dependent gel-shift assays were used for a
comparison of the ability of VD and EB1089 to stabilize VDR-RXR
heterodimers on these two VDRE types. The gel-shift assays revealed
EB1089 to be more sensitive for complexes on IP9-type VDREs than on
DR3-type VDREs. In addition, a gel-shift clipping method was
established to identify and compare complexes of ligand-stabilized
VDR-RXR heterodimers on different VDREs. On each VDRE, two complexes
could be discriminated that seemed to contain different functional
conformations of the VDR and allowed a more differential view on
DNA-complexed VDR-RXR heterodimers. The VDR-RXR conformation (which was
more ligand-sensitive) gained through EB1089 a higher affinity (7-fold)
for DNA binding and a more sensitive (9-fold) activation of an IP9-type
VDRE than of a DR3-type VDRE, whereas with the natural hormone VD, no
VDRE-type preference could be observed. This indicates that promoter
selectivity of VDR ligands is based on their property to selectively
increase affinity for VDREs and very sensitively stabilize VDR
conformations in VDR-RXR-VDRE complexes.
This article has been cited by other articles:
![]() |
F. Molnar, M. Perakyla, and C. Carlberg Vitamin D Receptor Agonists Specifically Modulate the Volume of the Ligand-binding Pocket J. Biol. Chem., April 14, 2006; 281(15): 10516 - 10526. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perakyla, M. Malinen, K.-H. Herzig, and C. Carlberg Gene Regulatory Potential of Nonsteroidal Vitamin D Receptor Ligands Mol. Endocrinol., August 1, 2005; 19(8): 2060 - 2073. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-N. Bastie, N. Balitrand, F. Guidez, I. Guillemot, J. Larghero, C. Calabresse, C. Chomienne, and L. Delva 1{alpha},25-Dihydroxyvitamin D3 Transrepresses Retinoic Acid Transcriptional Activity via Vitamin D Receptor in Myeloid Cells Mol. Endocrinol., November 1, 2004; 18(11): 2685 - 2699. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Bernardi, D. L. Trump, W.-D. Yu, T. F. McGuire, P. A. Hershberger, and C. S. Johnson Combination of 1{alpha},25-Dihydroxyvitamin D3 with Dexamethasone Enhances Cell Cycle Arrest and Apoptosis: Role of Nuclear Receptor Cross-Talk and Erk/Akt Signaling Clin. Cancer Res., December 1, 2001; 7(12): 4164 - 4173. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. FINCH, A. S. DUSSO, T. PAVLOPOULOS, and E. A. SLATOPOLSKY Relative Potencies of 1,25-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Inducing Differentiation and Markers of Bone Formation in MG-63 Cells J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1468 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. BROWN, J. FINCH, F. TAKAHASHI, and E. SLATOPOLSKY Calcemic Activity of 19-Nor-1,25(OH)2D2 Decreases with Duration of Treatment J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2088 - 2094. [Abstract] [Full Text] |
||||
![]() |
L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864. [Abstract] [Full Text] |
||||
![]() |
S. Kronenberg, C. Esser, and C. Carlberg An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling Nucleic Acids Res., June 15, 2000; 28(12): 2286 - 2291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herdick, Y. Bury, M. Quack, M. R. Uskokovic, P. Polly, and C. Carlberg Response Element and Coactivator-Mediated Conformational Change of the Vitamin D3 Receptor Permits Sensitive Interaction with Agonists Mol. Pharmacol., June 1, 2000; 57(6): 1206 - 1217. [Abstract] [Full Text] |
||||
![]() |
M. Quack and C. Carlberg The Impact of Functional Vitamin D3 Receptor Conformations on DNA-Dependent Vitamin D3 Signaling Mol. Pharmacol., February 1, 2000; 57(2): 375 - 384. [Abstract] [Full Text] |
||||